Koichi Matsuda

Has grant

University of Tokyo
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

デスモイド型線維腫症の病態に基づく診断、新規治療開発への学際的・国際的共同研究

Open Date: 2017-04-01

Close Date: 2021-03-31

Grant: Close

難治性希少肉腫である淡明細胞肉腫の治療標的となるゲノム異常の探索

Open Date: 2017-04-01

Close Date: 2020-03-31

Grant: Close

The development of treatment and the elucidation of the characteristics of tumor cells by exhaustive analysis of the p53 regulatory pathway

Open Date: 2016-04-01

Close Date: 2018-03-31

Grant: Close

Search of the fusion gene with the aim of re-construction of the identification and tumor concept of diagnostic markers in bone soft tissue tumor

Open Date: 2016-04-01

Close Date: 2021-03-31

Grant: Close

p53制御経路の網羅的解析による腫瘍細胞の特性の解明と治療法の開発

Open Date: 2016-04-01

Close Date: 2018-03-31

Articles (16)

Year:

2026

Aortic stenosis (AS) is a common valvular heart disease and has no pharmacological therapies. We performed a multi-ancestry genome-wide association meta-analysis of 86,864 AS cases among 2,853,408 individuals, discovering 241 autosomal independent risk loci and 3 X chromosome risk loci. We additionally performed sex-stratified and ancestry-stratified genome-wide association studies (GWASs), identifying an additional 5 sex-specific risk loci, 11 risk loci in European ancestry individuals and 1 risk locus in African ancestry individuals. We also performed a transcriptome-wide association study using expression quantitative trait loci from human aortic valves, discovering 54 new genes for which genetically predicted expression influences the risk of AS. We then generated a new polygenic risk score for AS. Finally, we performed gene silencing experiments targeting biologically relevant genes identified by our GWAS. Silencing of CMKLR1 and LTBP4 in human valvular interstitial cells substantially decreased mineralization, implicating a role for polyunsaturated fatty acids and transforming growth factor β signaling in AS.

Year:

2026

BRCA1 pathogenic variants are associated with a lower risk of developing prostate cancer than BRCA2, but aggressiveness remains unclear. Therefore, screening criteria are insufficiently established. Here, we reanalyzed the impact of BRCA1 pathogenic variants on aggressiveness using 11 300 prostate cancer patients, adjusting for age and area. The proportion of aggressive prostate cancer was higher in BRCA1 carriers (86.7%) than in noncarriers (61.1%) (odds ratio = 4.87; 95% confidence interval = 1.05 to 22.60). The proportion of high prostate-specific antigen levels was higher in BRCA1 carriers (66.7%) than in noncarriers (27.9%) (P = 7.61 × 10−3). BRCA1 carriers had a worse tendency than noncarriers for T classification (T3–4: BRCA1, 36.4%; noncarriers, 23.2%) and Gleason score (GS8–10: BRCA1, 53.3%; noncarriers, 31.0%). Moreover, we observed the first case of BRCA1-related aggressive prostate cancer showing long-term survival through early detection and multidisciplinary treatment. These results suggest that recommendations for early prostate cancer screening might need to be reconsidered for BRCA1 carriers.

Year:

2026

Clonal hematopoiesis of indeterminate potential (CHIP) has broad clinical relevance, and TP53 plays various roles within cells. However, the gene-specific and cross-disease significance of CHIP with TP53 mutations (TP53-CHIP) remains unclear. In this study, we evaluated TP53-CHIP using targeted sequencing data of 140,597 individuals without hematologic neoplasms in BioBank Japan. We identified 1,157 individuals with TP53-CHIP and clarified the characteristics of mutations and carriers. TP53-CHIP was associated with poor overall survival, especially because of lymphoid neoplasms and respiratory disease, in addition to myeloid neoplasms. Significant interactions accompanied by excess risks were observed between TP53-CHIP and lifestyle factors for disease-specific mortality: acetaldehyde exposure (resulting from the interaction between drinking and the germline variant of ALDH2) for myeloid neoplasms and smoking for respiratory disease. The clinical significance of TP53-CHIP was sometimes largely independent of variant allele fractions. These findings elucidate aspects of disease pathogenesis and inform personalized risk management. Significance: TP53-CHIP contributed to a wide range of outcomes besides myeloid neoplasm mortality. TP53-CHIP, when combined with environmental factors, showed a remarkably higher risk for disease-specific mortality, accompanied by excess risks.

Year:

2025

Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.

Year:

2025

Clonal hematopoiesis of indeterminate potential (CHIP) has broad clinical relevance, and TP53 plays various roles within cells. However, the gene-specific and cross-disease significance of CHIP with TP53 mutations ( TP53 -CHIP) remains unclear. In this study, we evaluated TP53 -CHIP using targeted sequencing data of 140,597 individuals without hematologic neoplasms in BioBank Japan. We identified 1,157 individuals with TP53 -CHIP and clarified the characteristics of mutations and carriers. TP53 -CHIP was associated with poor overall survival, especially because of lymphoid neoplasms and respiratory disease, in addition to myeloid neoplasms. Significant interactions accompanied by excess risks were observed between TP53 -CHIP and lifestyle factors for disease-specific mortality: acetaldehyde exposure (resulting from the interaction between drinking and the germline variant of ALDH2 ) for myeloid neoplasms and smoking for respiratory disease. The clinical significance of TP53 -CHIP was sometimes largely independent of variant allele fractions. These findings elucidate aspects of disease pathogenesis and inform personalized risk management. Significance: TP53 -CHIP contributed to a wide range of outcomes besides myeloid neoplasm mortality. TP53 -CHIP, when combined with environmental factors, showed a remarkably higher risk for disease-specific mortality, accompanied by excess risks.

Year:

2025

Clinical impact of TP53 -CHIP. A , TP53 -CHIP risk of mortality overall and across major disease categories (number of events: cardiovascular disease, 5,645; non-hematologic neoplasms, 13,256; nonneoplastic respiratory disease, 3,405; lymphoid neoplasms, 199; myeloid neoplasms, 162; and overall, 29,626). B, Sub-analysis of cardiovascular diseases (number of events: ischemic heart disease, 1,630; stroke, 1,649). C, Sub-analysis of non-hematologic neoplasms (number of events: liver cancer, 1,718; pancreatic cancer, 929; colorectal cancer, 1,897; gastric cancer, 1,751; breast cancer, 832; prostate cancer, 770; lung cancer, 2,833; and esophageal cancer, 593). D, Sub-analysis of nonneoplastic respiratory diseases (number of events: respiratory tract infection, 1,892; chronic lower respiratory tract disease, 440; and interstitial pneumonia, 410) are shown. HRs and their 95% CIs were estimated using Cox proportional hazards models of disease-specific mortality adjusted for age, sex, drinking habits, alcohol consumption, smoking habits, Brinkman index, body mass index, and comorbidities (hyperlipidemia, hypertension, diabetes, and cancer). All results among other models are shown in Supplementary Table S5. *, q q q

Year:

2025

Impact of smoking and TP53 -CHIP on respiratory disease mortality. A, The cause-specific survival from respiratory disease (nonneoplastic respiratory disease and lung cancer) was estimated using the Kaplan–Meier method. Smoking status was defined as ever smoker. B, HRs and their 95% CIs were estimated using Cox proportional hazards models of respiratory disease mortality adjusted for age, sex, drinking habits, alcohol consumption, Brinkman index, body mass index, and comorbidities (hyperlipidemia, hypertension, diabetes, and cancer).

Year:

2025

Mutation patterns and hotspot locations of TP53 -CHIP. A, Mutation patterns of CHIP in this study (1,198 mutations) and somatic mutations in the NCI TP53 database (RRID: SCR_026878; 28,310 mutations). B, Mutations that 10 or more individuals with TP53 -CHIP carry in this study are shown. The vertical axis represents the number of carriers. Detailed information of mutations is provided in Supplementary Table S2. C, Codon of the hotspot mutation, which accounted for more than 1% of all mutations, in the NCI TP53 database (RRID: SCR_026878). The vertical axis represents the proportion of mutations at each codon. Indel, insertion or deletion.

Year:

2025

Impact of acetaldehyde and TP53 -CHIP on myeloid neoplasm mortality. A, The cause-specific survival from myeloid neoplasms was estimated using the Kaplan–Meier method. Individuals prone to acetaldehyde exposure were defined as individuals with both rs671 Lys+ and ever-drinker status. B, HRs and their 95% CIs were estimated using Cox proportional hazards models of myeloid neoplasm mortality adjusted for age, sex, drinking habits, alcohol consumption, smoking habits, Brinkman index, body mass index, comorbidities (hyperlipidemia, hypertension, diabetes, and cancer), and ALDH2 . AcAld, acetaldehyde.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (66)

Kyuto Sonehara

Associate Professor

University of Tsukuba

JAPAN
View details

Tomáš Zima

Head of Institute

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC
View details

Kathleen Claes

Full professor

Ghent University Hospital

BELGIUM
View details

Giuseppe Matullo

-

ITALY
View details

Andrea Ganna

Professor at University of Helsinki

University of Helsinki

FINLAND
View details

Lisa Wiesmüller

Professor

Ulm University

GERMANY
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Radoslaw Debiec

NIHR Academic Clinical Lecturer in Platform Science

University of Leicester

UNITED KINGDOM
View details

Eric Hahnen

-

GERMANY
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Sara Lindström

University of Washington

UNITED STATES
View details

Maria Rossing

Associate Clinical Professor

Copenhagen University Hospital

DENMARK
View details

Marco Montagna

Istituto Oncologico Veneto

ITALY
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Nicoletta Resta

Full Professor Medical Genetics

University of Bari Aldo Moro

ITALY
View details

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Maria Piane

Sapienza University of Rome

ITALY
View details

Sara González

Institut Català d'Oncologia

SPAIN
View details

Yasuo Takahashi

Professor

Nihon University School of Medicine

JAPAN
View details

FEI CHEN

Assistant Professor

University of Southern California

UNITED STATES
View details

Ruth Loos

The Charles Bronfman Professor in Personalized Medicine

Københavns Universitet

DENMARK
View details

J. Gustav Smith

-

SWEDEN
View details

Chikashi Terao

RIKEN

JAPAN
View details

Takeshi Suzuki

Kanazawa University

JAPAN
View details

Alexandra Martins

INSERM

FRANCE
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Alexander E Volk

-

GERMANY
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Mariarosaria Calvello

European Institute of Oncology

ITALY
View details

anna coppa

Sapienza University of Rome

ITALY
View details

Allison DePersia

NorthShore University HealthSystem

UNITED STATES
View details

Kazuyoshi Ishigaki

Professor

Keio University

JAPAN
View details

Carlo Maj

Head of Bioinformatics | Research Group Leader – Genetic Epidemiology

University of Marburg

GERMANY
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Florentia Fostira

National Centre for Scientific Research-Demokritos

GREECE
View details

Paolo Radice

Head of Reserach Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Maria Elena. Martinez

University of California

UNITED STATES
View details

Marketa Janatova

Assistanf Professor and researcher

Přírodovědecká Fakulta, Univerzita Karlova

CZECH REPUBLIC
View details

Quinn Wells

Associate Professor of Medicine

Vanderbilt University Medical Center

UNITED STATES
View details

Eric Farber-Eger

Vanderbilt University Medical Center

UNITED STATES
View details

Gareth Evans

The University of Manchester

UNITED KINGDOM
View details

Weng Khong Lim

Assistant Professor

Duke-NUS Medical School

SINGAPORE
View details

Barbara Pasini

Associate Professor of Medical Genetics

Università degli Studi di Torino

ITALY
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Yoichiro Kamatani

Professor

University of Tokyo

JAPAN
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Jeffrey Weitzel

Professor and Director

University of Kansas Cancer Center

UNITED STATES
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paul Auer

Professor

Medical College of Wisconsin

UNITED STATES
View details

Saori Sakaue

University of Washington

UNITED STATES
View details

Ken Suzuki

Osaka University

JAPAN
View details

Sébastien Thériault

Associate Professor

Laval University

CANADA
View details

Alvaro Monteiro

Senior Member - Full Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Corinna Ernst

Hannover Medical School

GERMANY
View details

Ole Birger Pedersen

Professor

Zealand University Hospital

DENMARK
View details

Peter W. F. Wilson

-

UNITED STATES
View details

Kathryn Ruddy

Professor

Mayo Clinic

UNITED STATES
View details

Keiko Yamazaki

Lecturer

Chiba University Graduate School of Medicine

JAPAN
View details

Lidia Feliubadaló

Institut Català d'Oncologia

SPAIN
View details

Joanne Ngeow

Head

Nanyang Technological University (NTU)

SINGAPORE
View details

Zdenek Kleibl

Laboratory of oncogenetics (head)

Charles University, First Faculty of Medicine

CZECH REPUBLIC
View details

Nicholas Boddicker

Research Associate

Mayo Clinic

UNITED STATES
View details

Amanda Toland

Ohio State University

UNITED STATES
View details

Laura Cortesi

University of Modena and Reggio Emilia

ITALY
View details